Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bayer’s Xarelto Backed in Final Stroke Guidance From U.K.’s NICE

May 23 (Bloomberg) -- The U.K.’s National Institute for Health and Clinical Excellence published final guidance recommending Bayer AG’s Xarelto blood-thinner as a cost-effective way to prevent strokes in people with an irregular heartbeat known as atrial fibrillation.

Deciding whether to start treatment with the drug should be made after the patient and physician have discussed Xarelto’s risks and benefits compared with warfarin, an older treatment, the health-cost agency, known as NICE, said today in an e-mailed statement.

To contact the reporter on this story: Kristen Hallam in London at khallam@bloomberg.net

To contact the editor responsible for this story: Kristen Hallam at khallam@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.